SOURCE: Xtalks

Xtalks Webinars

September 08, 2017 07:30 ET

Reducing Clinical Trial Failure With New Tools for Drug Target Identification and Prioritization

TORONTO, ON--(Marketwired - September 08, 2017) - In an Xtalks webinar scheduled for Thursday, September 21, 2017 at 11am EDT (4pm BST/UK), experts from Clarivate Analytics will discuss new tools that can reduce clinical trial failure due to drug target identification and prioritization.

Finding new drugs and bringing them to market is a very long, research intensive process, taking on average 10 to 12 years1 and costing between $1.5 and $3 billion USD2. Data from the Centers for Medical Research (CMR) shows that less than one out of every 10 drugs that enter clinical trials makes it to market1 and over half of all clinical compounds fail because they are not effective against the target.3

Arguably the biggest reason for failure is that the wrong targets are chosen.4,5 In many cases no clear link is made between the target and disease, or the compounds have the wrong physiochemical properties to be effective. In other cases, there is just too much information from too many sources scattered in too many places to be able to get a complete picture of diseases, targets and animal models. Combining the right tools and workflows with the right data will lead to better decisions and more drugs to alleviate suffering.

This webinar will focus on new tools, which will allow scientists to:

  • Identify targets through genomic analysis
  • Prioritize them based on scientific, clinical and business rationale
  • Help select the most relevant animal model
  • Identify those with the greatest chance of success to market.

Several examples of the application of these tools will be discussed.

To learn more about this complimentary event visit: Reducing Clinical Trial Failure With New Tools for Drug Target Identification and Prioritization


Clarivate™ Analytics is the global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor® and Techstreet™. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission, to help our clients radically reduce the time from new ideas to life-changing innovations. For more information, please visit


Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical and biotech companies, private and academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit

For information about hosting a webinar visit


  2. DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ 47, 20-33, doi:10.1016/j.jhealeco.2016.01.012 (2016).
  3. Harrison, R. K. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov 15, 817-818, doi:10.1038/nrd.2016.184 (2016).
  4. Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13, 419-431, doi:10.1038/nrd4309 (2014).
  5. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17, 419-424, doi:10.1016/j.drudis.2011.12.020 (2012).

Image Available:

Contact Information